Moderna shares gain almost 4% after strong Phase 3 melanoma vaccine results and technical breakout

Traders Union
All News
Stocks
Moderna surges 3.98% today on news

Highlights

Moderna reported strong Phase 3 results for its personalized melanoma vaccine, showing significant reduction in recurrence and metastasis when combined with Keytruda.
The company secured FDA approval for its mRNA-based flu vaccine in August 2026 and continues to post revenue gains from its vaccine pipeline and international agreements.
Shares of Moderna are in a firm uptrend with bullish momentum, trading near session highs and expected to range between $186.5 and $247.03 over the next five days.

Strong buying flows as positive vaccine data drives optimism

Moderna reported a surge in activity following the release of positive Phase 3 data for its personalized melanoma vaccine, intismeran, developed with Merck. The trial showed that combining intismeran and Keytruda significantly reduced melanoma recurrence and distant metastasis compared to Keytruda alone, and Moderna plans to seek FDA approval in 2027. The company also obtained FDA approval in August 2026 for its mRNA-based flu vaccine and continued to post revenue gains linked to its expanding vaccine pipeline and international partnerships.

Anton Kharitonov, expert at Traders Union, notes that Moderna's technical momentum masks some underlying fragility. He highlights that temporary enthusiasm from positive trial results might overstate the long-term revenue visibility, as FDA approval for the melanoma vaccine is only expected in 2027. Kharitonov is wary of overbought momentum signals, warning that neutral CCI and short-term seller presence via Bull/Bear Power could precede a correction. He sees the volatile range and mixed oscillator backdrop as grounds for tactical caution. "Investors should be wary of chasing highs, as the risk of a pullback toward $186.5 remains tangible in the short term."

Viktoras Karapetjanc, expert at Traders Union, sees Moderna as fundamentally well positioned for continued upside. He believes the Series of positive regulatory milestones, such as future FDA approval for the melanoma vaccine and recent clearance for the flu shot, underline a strong growth trajectory. Karapetjanc finds the bullish technical structure reliable, noting that expanding global partnerships will likely reinforce investor confidence. "I expect further growth as Moderna's robust R&D pipeline and regulatory wins keep the bullish structure intact above $211.45."

Parshwa Turakhiya, analyst, highlights that market sentiment remains upbeat following the Phase 3 vaccine data. He observes that technicals suggest room for more gains, with resistance at $240.25 and strong support nearby. Turakhiya points to short-term volatility as a potential window for opportunistic moves if consolidation persists. "Given the current setup, I see attractive short-term trading opportunities as long as $211.45 holds as support."

Uptrend confirmed by robust momentum despite short-term divergence

Moderna is trading above its 20-day ($210.18), 50-day ($176.51), and 200-day ($83.8) moving averages, confirming bullish momentum for all key timeframes. The near-term resistance stands at $240.25, with initial support at $211.45 based on the Ichimoku Kijun, highlighting the strength of the uptrend. Momentum technicals are robust, as both the MACD and ADX indicators signal a strong upward bias. The RSI is at 53.03 and suggests a buy, while the Stochastic RSI is oversold at 14.14, indicating potential for further upside. Meanwhile, the CCI and Awesome Oscillator are neutral, and Bull/Bear Power at -2.9 points to short-term seller dominance. Intraday volatility is 16.06%, as the price recovers toward daily highs despite a mixed oscillator backdrop and short-term divergence.

Previously it was reported that analysts saw Moderna at a pivotal moment, with mixed technical signals and volatility following the release of its Phase 3 neoantigen therapy data in partnership with Merck. With the stock now demonstrating sustained bullish momentum and clear technical alignment, traders should closely monitor for a breakout above $240.25 as confirmation of continued upside potential.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.